AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in this application.

Claims 1-12. (Canceled)

13. (Currently Amended) A method for increasing binding of FKBP12.6 to RyR2 in a subject, or limiting a decrease in the level of RyR2-bound FKBP12.6 in a subject, comprising administering an effective amount of an agent to the subject, wherein the agent is described by the formula:



(g)

wherein

R_1 = OR' at position 7 on the benzothiazepine ring;

R' = alkyl;

R_2 = H;

R_3 = H;

R_4 = halide, ~~alkenyl,~~ carboxylic acid, or an alkyl containing ~~halogen,~~ O or S; and

m = 0, 1, or 2.

Claim 14. (Canceled)

15. (Original) The method of claim 13, wherein the subject is a human.

Claim 16. (Canceled)

17. (Previously Presented) The method of claim 13, wherein the subject has a cardiac condition selected from the group consisting of cardiac arrhythmia, tachycardia, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sustained ventricular tachycardia, non-sustained ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPVT), heart failure, sudden cardiac death and exercise-induced sudden cardiac death.

18. (Previously Presented) The method of claim 13, wherein the effective amount of the agent is one or more of:

(a) from about 5 mg/kg/day to about 20 mg/kg/day,

(b) an amount resulting in a plasma concentration of from about 0.02μM to about 1.0μM in the subject, or

(c) an amount resulting in a plasma concentration of from about 300 ng/ml to about 1000 ng/ml in the subject.

Claims 19 – 25. (Canceled)

26. (Currently Amended) The method of claim ~~25~~13, wherein the agent is

S36 

Claims 27 and 28. (Canceled)

29. (Previously Presented) A method for reducing the risk of sudden cardiac death, sustained ventricular tachycardia and non-sustained ventricular tachycardia in a subject, comprising administering an effective amount of an agent to the subject, wherein the agent is described by the formula:



(g)

wherein

R_1 = OR' at position 7 on the benzothiazepine ring;

R' = alkyl;

R_2 = H;

R_3 = H;

R_4 = halide, carboxylic acid, or an alkyl containing O or S; and

m = 0, 1, or 2.

30. (Previously Presented) The method of claim 29, wherein the agent is administered to a subject that has or is at risk of developing a condition selected from the group consisting of cardiac arrhythmia, tachycardia, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sustained ventricular tachycardia, non-sustained ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPVT), heart failure, sudden cardiac death and exercise-induced sudden cardiac death.

Claims 31 and 32. (Canceled)

33. (Previously Presented) The method of claim 29, wherein the effective amount of the agent is one or more of:

(a) from about 5 mg/kg/day to about 20 mg/kg/day,

(b) an amount resulting in a plasma concentration of from about 0.02μM to about 1.0μM in the subject, or

(c) an amount resulting in a plasma concentration of from about 300 ng/ml to about 1000 ng/ml in the subject.

34. (Canceled)

35. (Currently Amended) The method of claim ~~34~~29, wherein the agent is

S36 

Claims 36 - 42. (Canceled)

43. (Previously Presented) The method of claim 29, wherein the subject is a human.

Claims 44 - 48. (Canceled)

49. (Currently Amended) The method of claim 13, wherein R_4 = ~~alkenyl,~~ carboxylic acid~~, or an alkyl containing I or Br;~~ and m = 0 or 1.

50. (Previously Presented) The method of claim 13, wherein m = 0 or 1.

51. (Currently Amended) The method of claim 50, wherein R_4 = ~~alkenyl,~~ carboxylic acid~~, or an alkyl containing I or Br;~~ and R' = methyl.

52. (Currently Amended) The method of claim 51, wherein m = 0; and R_4 = ~~alkenyl or~~ carboxylic acid.

Claims 53 and 54. (Canceled)

55. (Previously Presented) The method of claim 29, wherein R_4 = carboxylic acid and m = 0 or 1.

56. (Previously Presented) The method of claim 29, wherein m = 0 or 1.

57. (Previously Presented) The method of claim 56, wherein R_4 = carboxylic acid and R' = methyl.

58. (Previously Presented) The method of claim 57, wherein m = 0; and R_4 = carboxylic acid.

59. (Currently Amended) A method for treating cardiac arrhythmia in a subject, comprising administering an effective amount of an agent to the subject, wherein the agent is described by the formula:



(g)

wherein

R_1 = OR' at position [[3]] 7 on the ~~phenyl~~ benzothiazepine ring;

R' = alkyl;

R_2 = H;

R_3 = H;

R_4 = halide, carboxylic acid, or an alkyl containing O or S; and

m = 0, 1, or 2.

60. (Previously Presented) The method of claim 59, wherein the effective amount of the agent is one or more of:

(a) from about 5 mg/kg/day to about 20 mg/kg/day,

(b) an amount resulting in a plasma concentration of from about 0.02μM to about 1.0μM in the subject, or

(c) an amount resulting in a plasma concentration of from about 300 ng/ml to about 1000

ng/ml in the subject.

61. (Canceled)

62. (Previously Presented) The method of claim 59, wherein the agent is S36 

63. (Previously Presented) The method of claim 59, wherein the subject is a human.

Claims 64 and 65. (Canceled)

66. (Previously Presented) The method of claim 59, wherein R_4 = carboxylic acid and m = 0 or 1.

67. (Previously Presented) The method of claim 59, wherein m = 0 or 1.

68. (Previously Presented) The method of claim 67, wherein R_4 = carboxylic acid and R' = methyl.

69. (Previously Presented) The method of claim 68, wherein m = 0; and R_4 = carboxylic acid.

Claims 70 to 73. (Cancelled)

74. (New) A method for increasing binding of FKBP12.6 to RyR2 in a subject, or limiting a decrease in the level of RyR2-bound FKBP12.6 in a subject, comprising administering an effective amount of an agent to the subject, wherein the agent is described by the formula:

S36 

75. (New) The method of claim 74, wherein the subject is a human.

76. (New) The method of claim 74, wherein the subject has a cardiac condition selected from the group consisting of cardiac arrhythmia, tachycardia, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sustained ventricular tachycardia, non-sustained ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPVT), heart failure, sudden cardiac death and exercise-induced sudden cardiac death.

77. (New) The method of claim 74, wherein the effective amount of the agent is one or more of:

(a) from about 5 mg/kg/day to about 20 mg/kg/day,

(b) an amount resulting in a plasma concentration of from about 0.02μM to about 1.0μM in the subject, or

(c) an amount resulting in a plasma concentration of from about 300 ng/ml to about 1000 ng/ml in the subject.